We report the development of a simplified PCR-based assay for the detection of Pneumocystis carinii DNA in clinical specimens. The adoption of a rapid DNA extraction procedure and the introduction of a type of enzyme-linked immunosorbent assay for PCR product detection enabled this procedure to be carried out in a single working day in a clinical microbiology laboratory. The PCR assay was prospectively compared with an immunofluorescent-antibody (FA) staining method for the detection of P. carinii in induced sputum and bronchoalveolar lavage (BAL) specimens. The results of the study showed that, for induced sputum specimens, FA staining had a sensitivity of 78% (32 of 41 specimens) and a specificity of 100% (166 of 166 specimens); PCR was 100% (41 of 41 specimens) sensitive and 98% (162 of 166 specimens) specific. For BAL specimens, FA staining was 100% sensitive (21 of 21 specimens) and 100% specific (133 of 133 specimens), and PCR had a sensitivity of 100% (21 of 21 specimens) and a specificity of 99%o (132 of 133 specimens). These results strongly suggest that use of our PCR-based assay could effect clinically useful improvements in the sensitivity of induced sputum specimens for the detection of P. carinii.
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Pneumocystis carinii pneumonia (PCP) is one of the most common and serious infectious manifestations of AIDS and is a significant problem in patients not infected with human immunodeficiency virus (HIV) who are receiving immunosuppressive therapy (9) .
The diagnosis of PCP in the laboratory has, until now, been dependent on visualization of P. carinii organisms in stained preparations of appropriate respiratory specimens. Conventional cytochemical stains, including Giemsa, methenamine silver (17) , and modified toluidine blue 0 (5); the nonspecific fluorescent stain calcofluor white (1); and specific monoclonal antibody-based fluorescent stains (11) have all been used for this purpose. A number of studies have demonstrated that the sensitivity of immunofluorescent-antibody (FA) staining exceeds those of the other available staining methods (2, 13) , and this technique is now well established, at least in the clinical microbiology laboratory, as the "gold standard" for the diagnosis of PCP.
The majority of laboratory diagnoses of PCP are made by using specimens obtained by bronchoalveolar lavage (BAL). Improved techniques for obtaining and processing induced sputa have led some institutions, including ours, to implement this technique as a less invasive alternative to BAL (6) . However, even in combination with immunofluorescence staining, the diagnostic sensitivity of this approach is somewhat variable, and some studies have shown that the use of induced sputum specimens is significantly less sensitive than the use of BAL specimens for the detection of P. carinii (4) . Primarily for this reason, the use of induced sputum specimens has not yet gained widespread acceptance as a less invasive alternative to the use of BAL specimens for PCP diagnosis.
In the past 2 years, there has been an accumulation of a body of literature describing PCR-mediated amplification of P.
carinii genes, including those encoding mitochondrial rRNA (8, 14, 16) , chromosomal rRNA (8, 10) , and thymidylate synthase (12) , as a technique for improving the diagnostic sensitivity of induced sputum. Although those studies reported potentially significant increases in the sensitivity of P. carinii detection by using PCR, the laborious natures of the DNA extraction and PCR product detection methodologies make this approach of questionable utility for clinical laboratories.
The present report described a PCR-based assay for the detection of P. carinii. The assay can be performed in a diagnostic laboratory in a clinically relevant time frame. The report also contains the results of a study prospectively comparing this technique with FA staining for the diagnosis of PCP from both induced sputum and BAL specimens. MATERIALS Determination of the relative sensitivities of PCR-EIA, agarose gel electrophoresis, and hybridization for detection of PCR product. PCR-amplified product was purified from agarose gels by electroelution and was extracted with phenolchloroform-isoamyl alcohol (25:24:1). DNA was then precipitated, dried under vacuum, and resuspended in TE buffer. The concentration of DNA was determined by measuring the absorbances of the solutions at 260 nm by using a UV spectrophotometer, and appropriate dilutions were prepared in TE buffer. Aliquots of these dilutions were subjected to agarose gel electrophoresis, PCR-EIA, and hybridization to determine the relative sensitivities of these methods for product detection. A slot blot procedure was used for hybridization; DNA was denatured by heating (95°C, 5 min) and was then applied to Hybond N+ membranes via a slot blot manifold (Life Technologies Inc., Gaithersburg, Md.). Membranes were subsequently probed, and hybrids were detected as described above.
FA staining. Detection of P. carinii by FA staining was performed by using a commercially available fluorescein isothiocyanate-conjugated murine monoclonal antibody directed against the major glycoprotein component of the cell wall of this organism (Genetic Systems, Redmond, Wash.). Induced sputum and BAL specimens were prepared for staining as described previously (6 infected with HIV and were receiving anti-P. carinii prophylaxis, and both subsequently developed FA staining-proven PCP at 4 and 6 weeks, respectively, after the original PCR-EIA-positive specimen was obtained. For the remaining two patients, FA staining-negative BAL specimens were obtained at the same time that the discrepant induced sputum specimens were obtained. One was a non-HIV-infected patient who had been diagnosed with PCP 4 months earlier, and the second was an HIV-positive patient who had been receiving anti-P. carinii prophylaxis for 4 years with no prior or subsequent (approximately 2 months) history of PCP.
Detection of P. carinii in BAL specimens. Twenty-one FA staining-positive BAL specimens were obtained, and all of these were positive by PCR-EIA (Table 2) . Of the 133 negative specimens, 132 were negative by both FA staining and PCR-EIA. Thus, PCR had a sensitivity of 100% and a specificity of 99% for the detection of P. carinii in BAL specimens. The single PCR-EIA-positive FA staining-negative BAL specimen (absorbance value, 0.27) was obtained from the non-HIVinfected patient with a prior history of PCP whose induced sputum specimen had also been PCR positive, and was confirmed to be PCR positive by Southern blotting.
DISCUSSION
The development of expedient, simple DNA extraction procedures and convenient product detection assays is essential if nucleic acid amplification-mediated detection of P. carinii is to become a more widely accessible diagnostic test. Our simple, yet efficient, DNA extraction procedure affords considerable savings in time and labor over previously published protocols for extracting DNA from P. carinii (8, 10, 12) since it obviates the need for phenolic extraction and ethanol precipitation. The microtiter plate format used in the PCR-EIA is one familiar to the majority of diagnostic laboratorians and, in addition to convenience and speed, offers sensitivity and specificity comparable to those of conventional methods for detecting products of PCR amplification. DNA (3, 15) , it seems unlikely that PCR detection of P. carinii in BAL specimens will prove to be of more than marginal diagnostic utility. Consequently, we performed the PCR-EIA on BAL specimens primarily to document further the high predictive value of positive and negative PCR-EIA results rather than to suggest that this technique be applied to the diagnosis of PCP from BAL specimens. The PCR-EIA is intermediate in sensitivity between electrophoresis and conventional hybridization, and our results with BAL and induced sputum specimens appear to support the hypothesis that the use of a less than maximally sensitive detection method is necessary to optimize the clinical utility of a PCR assay for P. carinii. We detected all FA staining-positive BAL specimens using PCR-EIA, but only one specimen, from a previously P. carinii-positive patient, was positive by PCR but negative by FA staining, giving PCR a specificity of 99%. In an institution that usually discontinues empiric anti-P. carinii therapy after a negative BAL specimen is obtained, only 3 of 105 patients with FA staining-negative PCR-negative BAL specimens subsequently developed PCP during a 2-to 9-month follow-up period. This result again demonstrates the value of an FA staining-negative BAL specimen in excluding a diagnosis of PCP and further illustrates the clinical sensitivity and specificity of our PCR assay.
In conclusion, the PCR-EIA offers a comparatively rapid and simple approach for using nucleic acid amplification technology to diagnose PCP. In view of the excellent clinical sensitivity and specificity of this technique on induced sputum specimens we envisage the use of PCR as an adjunct to FA staining for the detection of P. carinii in this type of specimen and anticipate that this will result in a significant decrease in the number of patients requiring an invasive procedure for diagnosing respiratory disease caused by this opportunistic pathogen. Although PCR-EIA also had a high degree of sensitivity and specificity for the detection of P. carinii in BAL specimens, the lack of evidence for a gain in clinically useful sensitivity when this technique is used in addition to FA staining strongly suggests that only in rare, problematic, cases could PCR have any utility in diagnosing PCP from BAL specimens.
